$MYO
MYOMO, INC.

2024 Q2 Form 10-Q Financial Statement

#000095017024055660 Filed on May 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $7.521M $3.754M $3.447M
YoY Change 26.22% 8.93% -10.89%
Cost Of Revenue $2.195M $1.455M $1.139M
YoY Change 30.87% 27.77% -11.69%
Gross Profit $5.326M $2.299M $2.308M
YoY Change 24.4% -0.37% -10.49%
Gross Profit Margin 70.81% 61.24% 66.95%
Selling, General & Admin $5.433M $5.232M $4.502M
YoY Change 12.73% 16.22% -3.32%
% of Gross Profit 102.02% 227.56% 195.07%
Research & Development $1.007M $956.2K $477.0K
YoY Change 78.51% 100.47% -27.68%
% of Gross Profit 18.91% 41.59% 20.67%
Depreciation & Amortization $35.97K $29.69K $48.63K
YoY Change -30.81% -38.96% 6.58%
% of Gross Profit 0.68% 1.29% 2.11%
Operating Expenses $6.441M $6.188M $4.979M
YoY Change 19.62% 24.29% -6.35%
Operating Profit -$1.115M -$3.889M -$2.671M
YoY Change 1.09% 45.59% -2.44%
Interest Expense $107.2K $135.3K $86.31K
YoY Change 3.68% 56.75% -11025.82%
% of Operating Profit
Other Income/Expense, Net $107.2K $135.3K $69.08K
YoY Change 25.73% 95.85% -8844.43%
Pretax Income -$1.008M -$3.753M -$2.602M
YoY Change -0.97% 44.26% -4.99%
Income Tax $113.8K $82.16K $42.41K
% Of Pretax Income
Net Earnings -$1.122M -$3.836M -$2.644M
YoY Change 10.6% 45.05% -6.06%
Net Earnings / Revenue -14.91% -102.16% -76.72%
Basic Earnings Per Share -$0.03 -$0.10 -$0.11
Diluted Earnings Per Share -$0.03 -$0.10 -$0.11
COMMON SHARES
Basic Shares Outstanding 28.81M 28.49M 20.92M
Diluted Shares Outstanding 37.37M 36.75M 24.20M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.264M
YoY Change -28.43%
Cash & Equivalents $5.846M $5.435M $9.264M
Short-Term Investments
Other Short-Term Assets $535.6K
YoY Change -43.08%
Inventory $2.601M $2.386M $1.565M
Prepaid Expenses
Receivables $2.526M $1.683M $1.548M
Other Receivables $0.00
Total Short-Term Assets $15.14M $15.71M $12.91M
YoY Change 19.88% 21.63% -22.24%
LONG-TERM ASSETS
Property, Plant & Equipment $289.3K $205.9K $190.7K
YoY Change 88.2% 7.96% -31.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $115.3K
YoY Change -42.07%
Other Assets $219.9K $4.955K $111.0K
YoY Change 98.04% -95.54% -0.34%
Total Long-Term Assets $1.049M $815.8K $824.0K
YoY Change 57.31% -1.0% -39.94%
TOTAL ASSETS
Total Short-Term Assets $15.14M $15.71M $12.91M
Total Long-Term Assets $1.049M $815.8K $824.0K
Total Assets $16.19M $16.52M $13.74M
YoY Change 21.76% 20.27% -23.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $906.8K
YoY Change -10.6%
Accrued Expenses $2.844M
YoY Change -21.8%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.465M $5.557M $3.934M
YoY Change 49.07% 41.24% -15.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $170.1K
YoY Change -62.56%
Total Long-Term Liabilities $170.1K
YoY Change -62.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.465M $5.557M $3.934M
Total Long-Term Liabilities $170.1K
Total Liabilities $6.513M $5.621M $4.104M
YoY Change 45.47% 36.96% -19.64%
SHAREHOLDERS EQUITY
Retained Earnings -$101.9M -$100.8M -$91.43M
YoY Change 10.22% 10.21% 13.01%
Common Stock $111.4M $111.5M $101.0M
YoY Change 10.08% 10.47%
Preferred Stock
YoY Change
Treasury Stock (at cost) $6.464K $6.464K $6.464K
YoY Change 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity $9.678M $10.90M $9.632M
YoY Change
Total Liabilities & Shareholders Equity $16.19M $16.52M $13.74M
YoY Change 21.76% 20.27% -23.59%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$1.122M -$3.836M -$2.644M
YoY Change 10.6% 45.05% -6.06%
Depreciation, Depletion And Amortization $35.97K $29.69K $48.63K
YoY Change -30.81% -38.96% 6.58%
Cash From Operating Activities -$1.916M -$3.246M -$1.817M
YoY Change 571.03% 78.65% -21.01%
INVESTING ACTIVITIES
Capital Expenditures $119.4K $59.81K $45.09K
YoY Change 697.33% 32.66% -9.61%
Acquisitions
YoY Change
Other Investing Activities $2.450M -$3.483M $0.00
YoY Change -183.09% -100.0%
Cash From Investing Activities $2.331M -$3.543M -$45.09K
YoY Change -178.64% 7757.52% -81.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 5.362M 5.772M
YoY Change -100.0% -7.11%
NET CHANGE
Cash From Operating Activities -1.916M -3.246M -1.817M
Cash From Investing Activities 2.331M -3.543M -45.09K
Cash From Financing Activities 0.000 5.362M 5.772M
Net Change In Cash 414.7K -1.437M 3.918M
YoY Change -112.73% -136.67% -251.73%
FREE CASH FLOW
Cash From Operating Activities -$1.916M -$3.246M -$1.817M
Capital Expenditures $119.4K $59.81K $45.09K
Free Cash Flow -$2.035M -$3.305M -$1.862M
YoY Change 577.32% 77.54% -20.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001369290
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-38109
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
MYOMO, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-0944526
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
137 Portland St.
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
4th Floor
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02114
CY2024Q1 dei City Area Code
CityAreaCode
617
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
996-9058
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2024Q1 dei Trading Symbol
TradingSymbol
MYO
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28814637
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5434726
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6871306
CY2024Q1 us-gaap Short Term Investments
ShortTermInvestments
5523664
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
1994662
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1683414
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2382658
CY2024Q1 us-gaap Inventory Net
InventoryNet
2386497
CY2023Q4 us-gaap Inventory Net
InventoryNet
1803507
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
676787
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
598850
CY2024Q1 us-gaap Assets Current
AssetsCurrent
15705088
CY2023Q4 us-gaap Assets Current
AssetsCurrent
13650983
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
604897
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
663554
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
205917
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
175794
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4955
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
91237
CY2024Q1 us-gaap Assets
Assets
16520857
CY2023Q4 us-gaap Assets
Assets
14581568
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4963707
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4885944
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
421514
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
486143
CY2024Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
171280
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
96461
CY2024Q1 us-gaap Deferred Income Current
DeferredIncomeCurrent
0
CY2023Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
8510
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5556501
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5477058
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
64599
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
115160
CY2024Q1 us-gaap Liabilities
Liabilities
5621100
CY2023Q4 us-gaap Liabilities
Liabilities
5592218
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28789823
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27135061
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28789796
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27135034
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
2881
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2715
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
111522270
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
105840239
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
147511
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
83669
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-100766441
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-96930809
CY2024Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
27
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
27
CY2024Q1 us-gaap Treasury Stock Value
TreasuryStockValue
6464
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
6464
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
10899757
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
8989350
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16520857
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14581568
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
1455345
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
1139074
CY2024Q1 us-gaap Gross Profit
GrossProfit
2299044
CY2023Q1 us-gaap Gross Profit
GrossProfit
2307634
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
956215
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
476991
CY2024Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2361845
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2030551
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2869751
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2471057
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
6187811
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
4978599
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3888767
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2670965
CY2024Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
135293
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
86314
CY2024Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-0
CY2023Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-31
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-17202
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
135293
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
69081
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3753474
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2601884
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
82158
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
42411
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3835632
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2644295
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36752597
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36752597
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24196732
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24196732
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.1
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3835632
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2644295
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
63842
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
65788
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
63842
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
65788
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3771790
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2578507
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
8989350
CY2024Q1 myo Proceeds From Sale Of Common Stock In Public Offering Net Of Offering Costs Value
ProceedsFromSaleOfCommonStockInPublicOfferingNetOfOfferingCostsValue
4598771
CY2024Q1 myo Proceeds From Sale Of Pre Funded Warrants Net Of Offering Costs
ProceedsFromSaleOfPreFundedWarrantsNetOfOfferingCosts
763138
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
320288
CY2024Q1 us-gaap Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax
UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
63842
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3835632
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
10899757
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6359365
CY2023Q1 myo Proceeds From Sale Of Common Stock In Public Offering Net Of Offering Costs Value
ProceedsFromSaleOfCommonStockInPublicOfferingNetOfOfferingCostsValue
3616094
CY2023Q1 myo Proceeds From Sale Of Pre Funded Warrants Net Of Offering Costs
ProceedsFromSaleOfPreFundedWarrantsNetOfOfferingCosts
2064012
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
171027
CY2023Q1 us-gaap Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax
UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
65788
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2644295
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
9631991
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-3835632
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-2644295
CY2024Q1 us-gaap Depreciation
Depreciation
29685
CY2023Q1 us-gaap Depreciation
Depreciation
48632
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
320288
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
171027
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
49053
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
CY2024Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
13000
CY2024Q1 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
0
CY2023Q1 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
-17202
CY2024Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
58658
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
101829
CY2024Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-63930
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-49012
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-718676
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-340533
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
597087
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
157148
CY2024Q1 myo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
-6897
CY2023Q1 myo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
53577
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
87041
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
386880
CY2024Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
77405
CY2023Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
39417
CY2024Q1 myo Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-115191
CY2023Q1 myo Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-109109
CY2024Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-11181
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-20093
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3245564
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1816690
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
59808
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45085
CY2024Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
2000000
CY2023Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
0
CY2024Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
5482757
CY2023Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3542565
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-45085
CY2024Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4598771
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3708045
CY2024Q1 myo Proceeds From At The Market Offering Net Of Offering Costs
ProceedsFromAtTheMarketOfferingNetOfOfferingCosts
763138
CY2023Q1 myo Proceeds From At The Market Offering Net Of Offering Costs
ProceedsFromAtTheMarketOfferingNetOfOfferingCosts
2064012
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5361909
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5772057
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-10360
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7311
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1436580
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3917593
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6871306
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5345967
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5434726
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9263560
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 1 — Description of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Myomo Inc. (“Myomo” or the Company”) is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro ® myoelectric upper limb orthosis product is registered with the U.S. Food and Drug Administration as a Class II medical device. The Company sells its products directly to patients, to Orthotics and Prosthetics ("O&amp;P") providers around the world, the Veterans Health Administration, and distributors in Europe and Australia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company was incorporated in the State of Delaware on September 1, 2004 and is headquartered in Boston, Massachusetts.</span></p>
CY2024Q1 myo Net Loss Income
NetLossIncome
3835600
CY2023Q1 myo Net Loss Income
NetLossIncome
2644300
CY2024Q1 myo Accumulated Deficit
AccumulatedDeficit
100766400
CY2023Q4 myo Accumulated Deficit
AccumulatedDeficit
96930800
CY2024Q1 myo Net Cash Provided By Used In Operating Activity
NetCashProvidedByUsedInOperatingActivity
3245600
CY2023Q1 myo Net Cash Provided By Used In Operating Activity
NetCashProvidedByUsedInOperatingActivity
1816700
CY2024Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1354218
CY2024Q1 myo Salesofprefundedwarrants
Salesofprefundedwarrants
224730
CY2024Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
3.8
CY2024Q1 myo Per Sale Price Of Warrants
PerSalePriceOfWarrants
3.7999
CY2024Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
5400000
CY2023Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
5413334
CY2023Q3 myo Salesofprefundedwarrants
Salesofprefundedwarrants
1920000
CY2023Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.6
CY2023Q3 myo Per Sale Price Of Warrants
PerSalePriceOfWarrants
0.5999
CY2023Q3 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
3900000
CY2023Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
13169074
CY2023Q1 myo Salesofprefundedwarrants
Salesofprefundedwarrants
6830926
CY2023Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.325
CY2023Q1 myo Per Sale Price Of Warrants
PerSalePriceOfWarrants
0.3249
CY2023Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
5700000
CY2024Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
3825615
CY2024Q1 us-gaap Short Term Investments
ShortTermInvestments
5523664
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
4893387
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from these estimates. The Company’s significant estimates include deferred tax valuation allowances, valuation of stock-based compensation, warranty obligations and reserves for slow-moving inventory.</span></p>
CY2024Q1 us-gaap Other Short Term Investments
OtherShortTermInvestments
5523700
CY2023Q4 us-gaap Other Short Term Investments
OtherShortTermInvestments
1994700
CY2024Q1 us-gaap Restructuring Reserve Translation Adjustment
RestructuringReserveTranslationAdjustment
63800
CY2023Q1 us-gaap Restructuring Reserve Translation Adjustment
RestructuringReserveTranslationAdjustment
65800
CY2024Q1 myo Percentage Of Direct Billing Channel Revenue Insures Represent
PercentageOfDirectBillingChannelRevenueInsuresRepresent
0.54
CY2023Q1 myo Percentage Of Direct Billing Channel Revenue Insures Represent
PercentageOfDirectBillingChannelRevenueInsuresRepresent
0.63
CY2024Q1 us-gaap Deferred Revenue
DeferredRevenue
0
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
8500
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3754389
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3446708
CY2024Q1 us-gaap Advertising Expense
AdvertisingExpense
787200
CY2023Q1 us-gaap Advertising Expense
AdvertisingExpense
691500
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
1994662
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1889805
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1378461
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0001
CY2024Q1 myo Common Stock Equivalents Pre Funded Warrants
CommonStockEquivalentsPreFundedWarrants
8496249
CY2023Q1 myo Common Stock Equivalents Pre Funded Warrants
CommonStockEquivalentsPreFundedWarrants
6830926
CY2024Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
800018
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
321484
CY2024Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
111192
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
6589
CY2024Q1 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1475287
CY2023Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1475434
CY2024Q1 us-gaap Inventory Net
InventoryNet
2386497
CY2023Q4 us-gaap Inventory Net
InventoryNet
1803507
CY2024Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
828873
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1073405
CY2024Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2249006
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1964487
CY2024Q1 myo Professional Fees Accrued Current
ProfessionalFeesAccruedCurrent
45832
CY2023Q4 myo Professional Fees Accrued Current
ProfessionalFeesAccruedCurrent
52202
CY2024Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
224424
CY2023Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
231108
CY2024Q1 myo Accrued Liabilities Customer Deposit
AccruedLiabilitiesCustomerDeposit
1497016
CY2023Q4 myo Accrued Liabilities Customer Deposit
AccruedLiabilitiesCustomerDeposit
1114979
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
118556
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
449763
CY2024Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
4963707
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
4885944
CY2023Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
13169074
CY2023Q1 myo Salesofprefundedwarrants
Salesofprefundedwarrants
6830926
CY2023Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.325
CY2023Q1 myo Per Sale Price Of Warrants
PerSalePriceOfWarrants
0.3249
CY2023Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
5700000
CY2023Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.0001
CY2023Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
5413334
CY2023Q3 myo Salesofprefundedwarrants
Salesofprefundedwarrants
1920000
CY2023Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.6
CY2023Q3 myo Per Sale Price Of Warrants
PerSalePriceOfWarrants
0.5999
CY2023Q3 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
3900000
CY2023Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.0001
CY2024Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1354218
CY2024Q1 myo Salesofprefundedwarrants
Salesofprefundedwarrants
224730
CY2024Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
3.8
CY2024Q1 myo Per Sale Price Of Warrants
PerSalePriceOfWarrants
3.7999
CY2024Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
5400000
CY2024Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.0001
CY2024Q1 myo Salesofprefundedwarrants
Salesofprefundedwarrants
0
CY2023Q1 myo Salesofprefundedwarrants
Salesofprefundedwarrants
0
CY2024Q1 myo Common Stock Equivalents Pre Funded Warrants
CommonStockEquivalentsPreFundedWarrants
8496249
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
300544
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
2821
CY2024Q1 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
0
CY2023Q1 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
0
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
320288
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
171027
CY2023Q4 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
55000
CY2024Q1 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company has a non-cancelable sublease agreement for its corporate headquarters in Boston, Massachusetts, which expires in January 2025 and a lease agreement for office space in Fort Worth, TX. which expires in December 2025. Termination options are either not included, or have expired, for the Company’s existing operating leases. Certain arrangements have discounted rent periods or escalating rent payment provisions. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheets. We recognize rent expense on a straight-line basis over the lease term.
CY2024Q1 myo Operating Lease Right Of Use Assets
OperatingLeaseRightOfUseAssets
604900
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
433830
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
102841
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
0
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
536671
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
50558
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
486113
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
421514
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
64599
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
486113
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
89496
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
125650
CY2024Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2024Q1 us-gaap Lease Cost
LeaseCost
89496
CY2023Q1 us-gaap Lease Cost
LeaseCost
125650
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y2M12D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.233
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.233
CY2023Q4 us-gaap Program Rights Obligations
ProgramRightsObligations
142217
CY2022Q4 us-gaap Program Rights Obligations
ProgramRightsObligations
56603
CY2024Q1 myo Payments To Supplier Finance Program Obligations
PaymentsToSupplierFinanceProgramObligations
0
CY2023Q1 myo Payments To Supplier Finance Program Obligations
PaymentsToSupplierFinanceProgramObligations
-128692
CY2024Q1 myo Expensed To Supplier Finance Program Obligations
ExpensedToSupplierFinanceProgramObligations
80109
CY2023Q1 myo Expensed To Supplier Finance Program Obligations
ExpensedToSupplierFinanceProgramObligations
132988
CY2024Q1 us-gaap Program Rights Obligations
ProgramRightsObligations
62108
CY2023Q1 us-gaap Program Rights Obligations
ProgramRightsObligations
52307

Files In Submission

Name View Source Status
0000950170-24-055660-index-headers.html Edgar Link pending
0000950170-24-055660-index.html Edgar Link pending
0000950170-24-055660.txt Edgar Link pending
0000950170-24-055660-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
myo-20240331.htm Edgar Link pending
myo-20240331.xsd Edgar Link pending
myo-ex31_1.htm Edgar Link pending
myo-ex31_2.htm Edgar Link pending
myo-ex32_1.htm Edgar Link pending
myo-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
myo-20240331_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending